Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Genitourinary System Neoplasm and descendants · 88% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… | Phase 1 / Phase 2 | terminated | Oct 10, 2022 | NextCure, Inc. | Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. | Sponsor / business decision |
| NCT04519879 | White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or… | Phase 2 | suspended | Aug 20, 2020 | City of Hope Medical Center | 05/26/2026 DSMC: Delinquent PMT reporting. | Other (stated, no rule matched) |
| NCT04899492 | Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy(RESPIRE) | N/A | terminated | May 24, 2021 | Institut Cancerologie de l'Ouest | lack of patient enrolment | Enrollment / accrual |
| NCT03991130 | High Dose IL-2 in Combination With Anti-PD-1 | Phase 2 | terminated | Jun 19, 2019 | Gregory Daniels | Lack of funding | Funding |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in… | Phase 1 | terminated | Feb 7, 2022 | Nuvectis Pharma, Inc. | Study terminated due to various reasons impacting the feasibility of future clinical development | Other (stated, no rule matched) |
| NCT00799110 | Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With… | Phase 2 | terminated | Nov 27, 2008 | Beth Israel Deaconess Medical Center | Withdrawal of funding | Funding |
| NCT05995236 | Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy | — | terminated | Aug 16, 2023 | Methodist Health System | So far, we have not been able to collect meaningful data for these patients which also led to our… | Other (stated, no rule matched) |
| NCT03152786 | Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | Phase 2 | terminated | May 15, 2017 | Wake Forest University Health Sciences | PIs not interested in continuing with the trial. | Other (stated, no rule matched) |
| NCT03869190 | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and… | Phase 1 / Phase 2 | terminated | Mar 11, 2019 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT04646434 | Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing… | N/A | suspended | Nov 30, 2020 | Roswell Park Cancer Institute | Protocol being updates and staff trained | Other (stated, no rule matched) |
| NCT03287271 | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase… | Phase 1 / Phase 2 | terminated | Sep 19, 2017 | Michael McHale | Due to loss of funding | Funding |
| NCT05703854 | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction… | Phase 1 / Phase 2 | suspended | Jan 30, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03031821 | Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome(PRIME) | Phase 3 | terminated | Jan 26, 2017 | Canadian Urologic Oncology Group | Manufacturer discontinued the production of study drugs. | Drug supply |
| NCT04974944 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in… | Phase 2 | terminated | Jul 23, 2021 | Sun Yat-Sen University Cancer Center | No superior PFS in study group among the enrolled patients. Company R\&D strategy shifted; funding… | Enrollment / accrual |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Phase 1 / Phase 2 | terminated | Jan 6, 2022 | Genmab | The Sponsor has made a strategic decision to stop the development of GEN1047. | Sponsor / business decision |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | Feb 6, 2023 | NuCana plc | The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373… | Sponsor / business decision |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 5, 2023 | Evopoint Biosciences Inc. | Strategic decision by Sponsor. | Sponsor / business decision |
| NCT06509919 | Application of a Novel Model Based on Plasma cfDNA Assay and MRl Imaging in the Detection… | — | suspended | Jul 19, 2024 | Shanghai Changzheng Hospital | Modifications to trial design | Other (stated, no rule matched) |
| NCT06586658 | Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or… | Early Phase 1 | suspended | Sep 19, 2024 | Shanghai Changzheng Hospital | Modifications to the trial design | Other (stated, no rule matched) |
| NCT00788307 | Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate… | Phase 1 | terminated | Nov 10, 2008 | Mayo Clinic | closed early due to poor accrual | Enrollment / accrual |
| NCT03786081 | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer… | Phase 1 / Phase 2 | terminated | Dec 24, 2018 | Seagen, a wholly owned subsidiary of Pfizer | Sponsor has decided to stop the trial based on strategic decisions | Sponsor / business decision |
| NCT05689021 | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate… | Phase 2 | terminated | Jan 18, 2023 | Mayo Clinic | Sponsor decided to close due to slow accrual and lack of efficacy | Efficacy / futility |
| NCT06666218 | Helping Ovarian Cancer Patients Cope With Their Illness (HOPE) | N/A | suspended | Oct 30, 2024 | Fred Hutchinson Cancer Center | Enrollment is currently paused. Aim 1 recruitment has finished, and the study team is preparing to… | Enrollment / accrual |
| NCT06226129 | Gadopiclenol in Contrast Enhanced MRI of the Prostate | Phase 4 | suspended | Jan 26, 2024 | Columbia University | The study is being transferred to another institution | Other (stated, no rule matched) |
| NCT04698564 | Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging | Phase 2 | terminated | Jan 7, 2021 | University of Maryland, Baltimore | "Study terminated due to institutional resource constraints, including limited availability of… | Safety / toxicity |
| NCT05067777 | Massage for Prostate Cancer-Related Fatigue (mPROSTATE)(mPROSTATE) | Phase 2 | terminated | Oct 5, 2021 | University of Utah | Lack of Funding | Funding |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT06376253 | A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers | Phase 1 | terminated | Apr 19, 2024 | Novartis Pharmaceuticals | Study termination based on sponsor decision due to lack of tolerability observed with… | Sponsor / business decision |
| NCT02432378 | Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC… | Phase 1 / Phase 2 | withdrawn | May 4, 2015 | Roswell Park Cancer Institute | opening up at a different site | Other (stated, no rule matched) |
| NCT04527900 | The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach | Phase 2 | terminated | Aug 27, 2020 | University of Maryland, Baltimore | SOC changed and low enrollment | Enrollment / accrual |
| NCT05422105 | Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient | — | suspended | Jun 16, 2022 | Primo Biotechnology Co., Ltd | Interim Analysis | Efficacy / futility |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating… | Phase 2 | terminated | Jun 6, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT05967533 | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With… | Phase 1 | suspended | Aug 1, 2023 | University of California, Davis | For internal interim analysis | Efficacy / futility |
| NCT04887935 | Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer | Phase 1 | terminated | May 14, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT07146113 | Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive…(PRIME) | — | suspended | Aug 28, 2025 | AstraZeneca | As a part of planned reassessment for the current period, a decision has been made to prioritize,… | Enrollment / accrual |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients… | Phase 3 | terminated | Nov 13, 2009 | National Cancer Institute (NCI) | The study was targeted to accrue 130 patients, but closed early for futility. | Efficacy / futility |
| NCT04346225 | Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in… | Phase 2 | suspended | Apr 15, 2020 | Ivan de Kouchkovsky, MD | Due to funding | Funding |
| NCT04581109 | Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer…(EPIDROP) | N/A | terminated | Oct 9, 2020 | University Hospital, Montpellier | Flaw in the analytical technique | Other (stated, no rule matched) |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients… | Phase 1 / Phase 2 | withdrawn | May 6, 2026 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT02389985 | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With… | Phase 1 / Phase 2 | terminated | Mar 17, 2015 | NewLink Genetics Corporation | Company decision | Sponsor / business decision |
| NCT05597878 | Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy | Phase 2 / Phase 3 | terminated | Oct 28, 2022 | Wake Forest University Health Sciences | Study initially suspended following an audit and need of amendment to address deficiencies. PI… | Other (stated, no rule matched) |
| NCT04745871 | Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in…(PREOP-PSMA) | N/A | terminated | Feb 9, 2021 | University Hospital, Brest | In the PREOP-PSMA protocol, written before 68Ga-PSMA-11 obtained Marketing Authorization. Today,… | Other (stated, no rule matched) |
| NCT05991752 | Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence…(ROMECO) | N/A | withdrawn | Aug 15, 2023 | University Hospital, Tours | feasibility issue | Other (stated, no rule matched) |
| NCT06185478 | Prostate Diffusion Imaging With Distortion Correction | N/A | withdrawn | Dec 29, 2023 | Norfolk and Norwich University Hospitals NHS Foundation Trust | Study abandoned due to COVID-19 (07/06/2024). | COVID-19 / pandemic |
| NCT06191575 | 7 Tesla MRI Neuroimaging in Testicular Cancer Patients With Hypogonadism and on Androgen… | — | suspended | Jan 5, 2024 | University of Southern California | Study team is conducting interim analysis. | Efficacy / futility |
| NCT04085237 | ESP Block for Laparoscopic Nephrectomy Surgeries(ESPB) | N/A | terminated | Sep 11, 2019 | McMaster University | It was terminated because of poor recruitment rate. | Enrollment / accrual |
| NCT04729387 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian… | Phase 3 | terminated | Jan 28, 2021 | Novartis Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT04955743 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal… | Phase 2 | terminated | Jul 9, 2021 | Yale University | Lack of activity in the drugs | Other (stated, no rule matched) |
| NCT05316467 | Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma | Phase 2 / Phase 3 | terminated | Apr 7, 2022 | Xiaojun Chen | no enough enrolled patients | Enrollment / accrual |
| NCT05523440 | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer… | Phase 2 | terminated | Aug 31, 2022 | University of Oklahoma | Funding issue | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 13, 2026source: clinicaltrials